PortfoliosLab logo
InflaRx N.V. (IFRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

NL0012661870

CUSIP

001266187

IPO Date

Nov 8, 2017

Highlights

Market Cap

$54.37M

EPS (TTM)

-$0.84

Total Revenue (TTM)

$129.75K

Gross Profit (TTM)

-$2.98M

EBITDA (TTM)

-$45.87M

Year Range

$0.71 - $2.82

Target Price

$3.62

Short %

1.56%

Short Ratio

3.99

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


InflaRx N.V.

Popular comparisons:
IFRX vs. SCHD
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

InflaRx N.V. (IFRX) returned -67.51% year-to-date (YTD) and -43.88% over the past 12 months.


IFRX

YTD

-67.51%

1M

-52.79%

6M

-67.38%

1Y

-43.88%

3Y*

-20.38%

5Y*

-38.09%

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of IFRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-2.43%-42.32%-26.62%66.67%-52.79%-67.51%
2024-0.61%9.88%-13.48%-11.04%4.38%21.68%-13.79%6.00%-3.77%1.31%58.71%0.41%51.53%
2023-30.00%-10.83%0.26%151.03%-13.96%6.44%-6.05%-5.73%-24.56%-43.29%-20.12%20.74%-47.42%
2022-25.00%-25.49%-31.20%-7.65%-5.92%-8.81%88.97%-19.34%19.46%-1.52%-0.00%19.23%-34.87%
20216.16%-22.28%-6.02%-2.56%-19.74%-2.62%-12.46%-1.15%0.78%63.71%18.16%-4.99%-5.37%
2020-18.43%31.27%-9.91%85.08%24.75%-47.96%9.37%-12.35%-3.18%-10.33%8.12%21.79%27.02%
2019-9.84%13.02%1.97%21.96%-21.91%-91.22%-5.70%-4.70%-13.03%7.29%28.30%16.47%-89.11%
201814.32%8.94%10.54%35.75%-2.58%-15.44%-5.21%11.19%0.97%-6.18%-9.25%24.47%73.60%
201742.09%-1.64%39.76%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of IFRX is 25, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of IFRX is 2525
Overall Rank
The Sharpe Ratio Rank of IFRX is 2626
Sharpe Ratio Rank
The Sortino Ratio Rank of IFRX is 3737
Sortino Ratio Rank
The Omega Ratio Rank of IFRX is 3838
Omega Ratio Rank
The Calmar Ratio Rank of IFRX is 2121
Calmar Ratio Rank
The Martin Ratio Rank of IFRX is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for InflaRx N.V. (IFRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

InflaRx N.V. Sharpe ratios as of May 31, 2025 (values are recalculated daily):

  • 1-Year: -0.43
  • 5-Year: -0.37
  • All Time: -0.31

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of InflaRx N.V. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


InflaRx N.V. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the InflaRx N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the InflaRx N.V. was 98.58%, occurring on May 28, 2025. The portfolio has not yet recovered.

The current InflaRx N.V. drawdown is 98.45%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.58%Apr 24, 20191533May 28, 2025
-43.73%May 2, 2018162Dec 20, 201851Mar 7, 2019213
-23.57%Mar 15, 201913Apr 2, 20199Apr 15, 201922
-18.47%Feb 26, 20183Feb 28, 201829Apr 11, 201832
-17.46%Dec 1, 20174Dec 6, 201712Dec 22, 201716
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of InflaRx N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of InflaRx N.V., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 27.8% positive surprise.


-0.50-0.40-0.30-0.20-0.100.0020212022202320242025
-0.13
-0.18
Actual
Estimate

Valuation

The Valuation section provides an overview of how InflaRx N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for IFRX relative to other companies in the Biotechnology industry. Currently, IFRX has a P/S ratio of 419.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for IFRX in comparison with other companies in the Biotechnology industry. Currently, IFRX has a P/B value of 0.7. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items